Article Information
History
- February 27, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Azadeh Shoaibi, PhD, MHS1,*,
- Kathryn Matuska, BA2,*,
- Patricia C. Lloyd, PhD, ScM1,#,
- Hui Lee Wong, PhD1,
- Joann F. Gruber, PhD1,
- Tainya C. Clarke, PhD1,
- Sylvia Cho, PhD1,
- Emily Lassman, MS2,
- Hai Lyu, MS2,
- Rowan McEvoy, BS2,
- Zhiruo Wan, MSE2,
- Mao Hu, BS2,
- Sandia Akhtar, BS2,
- Yixin Jiao, MPP2,
- Yoganand Chillarige, MPA2,
- Daniel Beachler, PhD3,
- Alex Secora, PhD4,
- Nandini Selvam, PhD, MPH4,
- Djeneba Audrey Djibo, PhD, MSBME5,
- Cheryl N McMahill Walraven, MSW, PhD5,
- John D. Seeger, DrPH, PharmD6,
- Kandace L. Amend, PhD6,
- Jennifer Song, MA, MURP6,
- Robin Clifford, MS, BS6,
- Jeffrey A. Kelman, PhD7,
- Richard A. Forshee, PhD1 and
- Steven A. Anderson, PhD1
- 1US Food and Drug Administration, Silver Spring, MD, USA
- 2Acumen LLC, Burlingame, CA, USA
- 3Carelon Research, Wilmington, DE, USA
- 4IQVIA, Falls Church, VA, USA
- 5CVS Health/Aetna, Blue Bell, Pennsylvania, USA
- 6Optum Epidemiology, Boston, MA, USA
- 7Centers for Medicare & Medicaid Services, Washington, DC, USA
- ↵#Corresponding
Author Patricia C. Lloyd, PhD, ScM, Office of Biostatistics and Pharmacovigilance Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Ave., Building 71 Silver Spring, MD 20993, Email: patricia.lloyd{at}fda.hhs.gov
Posted February 27, 2024.
Risk of Adverse Events Following Monovalent Third or Booster Dose of COVID-19 mRNA Vaccination in U.S. Adults Ages 18 Years and Older
